Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Vaxcyte, Inc.
Report date December 30, 2022 · Filed January 04, 2023
Section 16 reporting ended · disclosed 2023-01-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.95 · Expires 2032-12-30 | Direct | 15,000 |
Reported balance
After 2022-12-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-12-30 · Grant · Acquired 15,000 · Balance 15,000 F2: 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. |
| Common StockSEC Table I · non-derivative | Direct | 17,827 |
Reported balance
Holding disclosure · report date 2022-12-30 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 17,827 F1: Includes 684 shares acquired under the Issuer's Employee Stock Purchase Plan on November 17, 2022. |
| Common StockSEC Table I · non-derivative | IndirectBy Fairman Family Trust | 286,227 |
Reported balance
Holding disclosure · report date 2022-12-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 286,227 |
| Common StockSEC Table I · non-derivative | IndirectBy AF 2020 Irrevocable Trust | 50,000 |
Reported balance
Holding disclosure · report date 2022-12-30 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 50,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 684 shares acquired under the Issuer's Employee Stock Purchase Plan on November 17, 2022.
F2: 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 22, 2021 Filed Apr 23, 2021 19:31 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 2,793 | $1.79 | $4,999.47 |
DisclosureSEC source: 0001209191-21-028190 · doc4.xml · nonDerivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 20:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001209191-21-025763 · doc4.xml · derivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-03-31 F1 · derivative.exercise_date: 1/48 of shares subject to the option vest on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| March 26, 2021 Filed Mar 29, 2021 19:18 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 4,750 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-023482 · doc4.xml · derivative · entry 6 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,259 Underlying: Common Stock · 4,750 shares Expires 2025-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| March 26, 2021 Filed Mar 29, 2021 19:18 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,361 | $24.48 | $33,317.28 |
DisclosureSEC source: 0001209191-21-023482 · doc4.xml · nonDerivative · entry 3 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,408 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $24.15 to $24.77. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 26, 2021 Filed Mar 29, 2021 19:18 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,389 | $23.64 | $80,115.96 |
DisclosureSEC source: 0001209191-21-023482 · doc4.xml · nonDerivative · entry 2 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,769 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $23.125 to $24.04. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 26, 2021 Filed Mar 29, 2021 19:18 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 4,750 | $0.04 | $190.00 |
DisclosureSEC source: 0001209191-21-023482 · doc4.xml · nonDerivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 17:37 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 4,750 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-016339 · doc4.xml · derivative · entry 7 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,009 Underlying: Common Stock · 4,750 shares Expires 2025-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 17:37 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 68 | $25.33 | $1,722.44 |
DisclosureSEC source: 0001209191-21-016339 · doc4.xml · nonDerivative · entry 4 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,408 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.23 to $25.41. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 17:37 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,372 | $24.34 | $33,394.48 |
DisclosureSEC source: 0001209191-21-016339 · doc4.xml · nonDerivative · entry 3 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,476 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $24.13 to $24.94. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 17:37 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,310 | $23.73 | $78,546.30 |
DisclosureSEC source: 0001209191-21-016339 · doc4.xml · nonDerivative · entry 2 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,848 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $23.08 to $24.075. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 17:37 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 4,750 | $0.04 | $190.00 |
DisclosureSEC source: 0001209191-21-016339 · doc4.xml · nonDerivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 16:36 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 4,750 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-005892 · doc4.xml · derivative · entry 6 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,759 Underlying: Common Stock · 4,750 shares Expires 2025-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 16:36 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 425 | $25.94 | $11,024.50 |
DisclosureSEC source: 0001209191-21-005892 · doc4.xml · nonDerivative · entry 3 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,408 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.885 to $26.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 16:36 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,325 | $25.20 | $108,990.00 |
DisclosureSEC source: 0001209191-21-005892 · doc4.xml · nonDerivative · entry 2 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,833 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $24.82 to $25.745. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 16:36 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 4,750 | $0.04 | $190.00 |
DisclosureSEC source: 0001209191-21-005892 · doc4.xml · nonDerivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 20:26 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 740 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-20-065598 · doc4.xml · derivative · entry 4 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,629 Underlying: Common Stock · 740 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 4, 2018, and 1/48th of the shares vest monthly thereafter. Read SEC document |
| December 29, 2020 Filed Dec 30, 2020 20:26 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 740 | $1.79 | $1,324.60 |
DisclosureSEC source: 0001209191-20-065598 · doc4.xml · nonDerivative · entry 1 Fairman Jeff · CIK 0001813800 · VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 668 shares acquired under the Employee Stock Purchase Plan on November 17, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.